Why Moderna, Inc. (MRNA) Stock Rose 12.3% on Sep 21, 2026
What happened
Moderna surged +13.25% to $174.46 after announcing its Phase 3 melanoma vaccine trial (intismeran autogene, co-developed with Merck) earned a prestigious Presidential Symposium slot at the European Society for Medical Oncology (ESMO) Congress 2026 on October 24. Yahoo Finance and Morningstar cited the announcement as the driver. Medical congresses reserve these slots for practice-changing clinical datasets, and markets interpreted the selection as a strong signal ahead of data presentation.
ESMO Congress presentation of Phase 3 INTerpath-001 data on October 24, 2026; MRNA earnings on 2026-11-05 (date not yet confirmed, consensus EPS estimate −$1.38).
Frequently asked questions
Why did Moderna, Inc. (MRNA) stock rise on Sep 21, 2026?
Moderna surged +13.25% to $174.46 after announcing its Phase 3 melanoma vaccine trial (intismeran autogene, co-developed with Merck) earned a prestigious Presidential Symposium slot at the European Society for Medical Oncology (ESMO) Congress 2026 on October 24. Yahoo Finance and Morningstar cited the announcement as the driver. Medical congresses reserve these slots for practice-changing clinical datasets, and markets interpreted the selection as a strong signal ahead of data presentation.
How much did MRNA stock rise on Sep 21, 2026?
MRNA rose 12.3% during the Sep 21, 2026 trading session.